

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER PURSUANT TO RULE 13a-16 AND 15d-16 UNDER  
THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November 2013

File No. 000-54598

**Stellar Biotechnologies Inc.**

(Name of Registrant)

**332 E. Scott Street, Port Hueneme, CA 93041**

(Address of principal executive offices)

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.  
FORM 20-F  FORM 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Form 6-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Stellar Biotechnologies Inc.  
(Registrant)

Dated: November 25, 2013

By: /s/ "Kathi Niffenegger"  
Kathi Niffenegger  
Chief Financial Officer

**Exhibits:**

99.1 News Release dated November 25, 2013

## **Stellar Biotechnologies to Present at 6<sup>th</sup> Annual LD Micro Conference December 4, 2013**

**PORT HUENEME, CA, (November 25, 2013) -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX-V: KLH)**, the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), announced today that the Company's President and CEO Frank Oakes will present at the Sixth Annual LD Micro Conference to be held at the Luxe Sunset Boulevard Hotel in Los Angeles, on December 4, 2013 at 8:00 am PT.

Mr. Oakes will provide an update on the Company's Stellar KLH™ technology, recent accomplishments, and 2014 objectives. His presentation will be followed by a breakout Q&A session. Additional members of Stellar's executive team will attend and be available to discuss the Company's programs over the 3-day event.

Please contact the LD Micro Conference organizers to attend the event at [www.ldmicro.com](http://www.ldmicro.com), or Mark McPartland with Stellar Biotechnologies at [markmcp@stellarbiotech.com](mailto:markmcp@stellarbiotech.com) to arrange a meeting with Stellar's management.

Stellar Biotechnologies' presentation details:

Date: December 4, 2013  
Time: 8:00 am PT  
Location: The Luxe Sunset Boulevard Hotel, Los Angeles – Track 2

The presentation will be available on the Stellar Biotechnologies website following the event at [http://stellarbiotechnologies.com/investors/profile\\_presentations/](http://stellarbiotechnologies.com/investors/profile_presentations/)

### **About LD MICRO**

LD MICRO is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by institutional investors. It is a non-registered investment advisor. If you are a private or institutional investor interested in learning more about the conference, or wish to attend, please contact Eric Lahiji ([Eric@ldmicro.com](mailto:Eric@ldmicro.com)).

### **About Stellar Biotechnologies, Inc.**

**Stellar Biotechnologies, Inc. (U.S. OTCQB: SBOTF) (TSX-V: KLH)** is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

To receive regular updates, enter email at <http://stellarbiotechnologies.com/contact/>

Visit [www.StellarBiotech.com](http://www.StellarBiotech.com) and the KLH knowledge base [www.KLHSite.com](http://www.KLHSite.com).

### **Company Contacts:**

Frank Oakes  
President and CEO  
Phone +1 (805) 488-2800  
[investorrelations@stellarbiotech.com](mailto:investorrelations@stellarbiotech.com)

Mark A. McPartland  
Vice President of Corporate Development and Communications  
Phone: +1 (805) 488-2800  
[markmcp@stellarbiotech.com](mailto:markmcp@stellarbiotech.com)  
[www.stellarbiotech.com](http://www.stellarbiotech.com)

### **Forward Looking Statements**

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of these releases.

